Figure 5.

Reduced TRDMT1 expression renders cisplatin sensitization in vivo. (A) Lv-shTRDMT1 or Lv-NC transfected SKOV3 cells were subcutaneously injected into BALB/c nude mice, a week after injection, cisplatin (5 mg/kg) or saline was injected into the center of the xenograft tumors twice per week for three consecutive weeks. (B) Representative images of tumors in xenografts transfected with LV-shTRDMT1/LV-NC with saline or cisplatin treatment. (C) Tumor size of SKOV3 subcutaneous xenograft tumors (n = 6, mean ± SD). (D) WB for TRDMT1 in tumor tissues collected from mice in each group (tissues from six tumors in the same group were mixed into one sample). (E) Representative photographs of m5C staining and TUNEL analysis in tumors treated as indicated above. (FandG) IHC of TRDMT1 and KI-67 expression in ovarian cancer tissues of patients who were platinum-sensitive (PFS > 6) and -resistant (PFS < 6) (F). Staining was assessed and scored on a scale of 0 (<5% staining) to 4 (>75% staining) in (G). Quantification of IHC staining (n = 38, PFS > 6, n = 24; PFS < 6, n = 14) was shown.